Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
T.MAN Pharmaceutical PCLBKK:TMAN 19 Return-on-Tangible-Asset is 10.22% as of Jun. 2026, which is 37% below its 10-year median of 16.35. GuruFocus rates BKK:TMAN with a GF Score™ of 19/100. Among 1,007 Drug Manufacturers companies, T.MAN Pharmaceutical PCL ranks better than 87.09% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. T.MAN Pharmaceutical PCL's annualizedNet Income for the quarter that ended in Jun. 2026 was ฿390 Mil. T.MAN Pharmaceutical PCL's average total tangible assets for the quarter that ended in Jun. 2026 was ฿3,819 Mil. Therefore, T.MAN Pharmaceutical PCL's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 10.22%.
The historical rank and industry rank for T.MAN Pharmaceutical PCL's Return-on-Tangible-Asset or its related term are showing as below:
BKK:TMAN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 13.68 Med: 16.35 Max: 20.87
Current: 13.68
During the past 4 years, T.MAN Pharmaceutical PCL's highest Return-on-Tangible-Asset was 20.87%. The lowest was 13.68%. And the median was 16.35%.
BKK:TMAN's Return-on-Tangible-Asset is ranked better than 87.09% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.84
vs BKK:TMAN: 13.68
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
T.MAN Pharmaceutical PCL Return-on-Tangible-Asset Related Terms
T.MAN Pharmaceutical PCL Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for T.MAN Pharmaceutical PCL's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:TMAN vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, T.MAN Pharmaceutical PCL's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
T.MAN Pharmaceutical PCL Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, T.MAN Pharmaceutical PCL's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where T.MAN Pharmaceutical PCL's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 10.22% mean?
T.MAN Pharmaceutical PCL (BKK:TMAN) has a Return-on-Tangible-Asset of 10.22% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on T.MAN Pharmaceutical PCL and its competitors. This is 37% below median its historical median of 16.35. Over the past decade, T.MAN Pharmaceutical PCL's Return-on-Tangible-Asset has ranged from 13.68 to 20.87. According to the industry distribution chart, T.MAN Pharmaceutical PCL ranks #130 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 12.9%.
Is T.MAN Pharmaceutical PCL's Return-on-Tangible-Asset too high?
T.MAN Pharmaceutical PCL's current Return-on-Tangible-Asset of 10.22% is 37% below median its 10-year median of 16.35. Over the past 10 years, this metric has ranged from a low of 13.68 to a high of 20.87. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.84. T.MAN Pharmaceutical PCL's value of 10.22% is 259.9% above this industry median. Based on the distribution chart, T.MAN Pharmaceutical PCL ranks #130 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, T.MAN Pharmaceutical PCL has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does T.MAN Pharmaceutical PCL's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, T.MAN Pharmaceutical PCL ranks #130 out of 1007 companies for Return-on-Tangible-Asset. This places T.MAN Pharmaceutical PCL in the top 13% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.84. T.MAN Pharmaceutical PCL's value of 10.22% is 259.9% above this benchmark. Historically, T.MAN Pharmaceutical PCL's own Return-on-Tangible-Asset has ranged from 13.68 to 20.87 over the past decade. While the company's 10-year median is 16.35 vs. the industry median of 2.84, T.MAN Pharmaceutical PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.84, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. T.MAN Pharmaceutical PCL's current Return-on-Tangible-Asset of 10.22% is 259.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on T.MAN Pharmaceutical PCL and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. T.MAN Pharmaceutical PCL's current Return-on-Tangible-Asset is 10.22%, which is 37% below median its own 10-year median of 16.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is T.MAN Pharmaceutical PCL stock overvalued right now?
T.MAN Pharmaceutical PCL (BKK:TMAN) has a current Return-on-Tangible-Asset of 10.22%. The current Return-on-Tangible-Asset is 10.22%, which is 37% below median its 10-year median of 16.35 and 259.9% above the Drug Manufacturers industry median of 2.84. T.MAN Pharmaceutical PCL's overall GF Score™ is 19/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For T.MAN Pharmaceutical PCL (BKK:TMAN), the current Return-on-Tangible-Asset is 10.22% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
T.MAN Pharmaceutical PCL is engaged in purchasing, importing, manufacturing, and distributing original equipment and in manufacturing, distributing, and exporting modern medicines, traditional medicines, dietary supplements, and healthcare products for the healthcare industry. It offers products through brands such as T.Nutrition, T.Derma, Mommy&Me, TMT, Heaven Herb, and T.Pharmaceutical. The company's reportable segments are: Segment for manufactured products under own brand, which derives key revenue, Segment for manufactured products under third parties' brand, and Segment for trading products.
19GF Score
Get the complete analysis for BKK:TMAN
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:TMAN has been successfully added to your 
